Anti-CV2/CRMP5 antibodies are most often associated with SCLC and thymoma, whereas the most common clinical manifestations include peripheral neuropathy, uveitis, and cerebral ataxia, the latter of which was reported in our case [19]. Here, DPYSL5 is linked to small cell lung carcinoma.